Christopher Stroh
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 13, 2024
Patients With Advanced Non-small Cell Lung Cancer Harboring MET Alterations: A Descriptive Cohort Study.
Journal: Clinical lung cancer
Published: August 21, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Journal: The Lancet. Oncology
Published: January 19, 2024
Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC.
Journal: Clinical colorectal cancer
Published: December 18, 2023
Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition.
Journal: Acta neuropathologica communications
Published: November 30, 2022
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.
Journal: Cell reports. Medicine
Published: October 05, 2022
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Journal: Molecular cancer therapeutics
Published: September 09, 2022
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 20, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
Journal: JCO precision oncology
Published: March 30, 2021
Real-world insights into patients with advanced NSCLC and MET alterations.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 22, 2021
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 19, 2020
Last Updated: 09/26/2026